
Renovaro Investor Relations Material
Latest events

Q3 2025
15 May, 2025

Q2 2025
19 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Renovaro Inc
Access all reports
Renovaro Inc. is a biotechnology company focused on developing advanced allogeneic cell and gene therapies. These therapies are designed to enhance immune system responses with the potential for long-term or life-long remission in some of the most challenging cancers, as well as the treatment or possible cure of serious infectious diseases, including HIV and Hepatitis B virus (HBV). The company leverages its proprietary platforms in gene and cell therapy to create therapeutic candidates aimed at hyper-stimulating the immune system to target and destroy cancer cells and virus-infected cells. Renovaro Inc. is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.
Key slides for Renovaro Inc


Investor Presentation
Renovaro Inc


Investor Presentation
Renovaro Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
RENB
Country
🇺🇸 United States